Is Coya Therapeutics, Inc. Common Stock (COYA) overvalued? · rev $3.6M
Coya Therapeutics, Inc. Common Stock (COYA) is a biotechnology company listed on NASDAQ.
This page asks whether Coya Therapeutics, Inc. Common Stock (COYA) looks expensive on cached numbers — not a short thesis.
Latest reported COYA revenue for 2024-12-31 was $3.6M. Net income was -$14.9M. Revenue was down 40.8% from 2023-12-31 to 2024-12-31. COYA currently screens at market cap $118.0M.
COYA currently screens at market cap $118.0M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next COYA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the COYA stock page for the full model, not this heading.
Not investment advice.